10-Q quarterly report · filed Nov 12, 2026

USANA HEALTH SCIENCES INC (USNA) Q4 2026 10-Q Quarterly Report

Short answer

USANA HEALTH SCIENCES INC (USNA) filed its Q4 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Oct 3, 2026. Quarterly revenue was $206M (down 3.6% year over year) with net income of −$6M.

Q4 2026 key financials · XBRL

Revenue
$206M
−3.6% YoY · −7.8% QoQ
Net income
−$6M
+14.8% YoY · +74.0% QoQ
Operating margin
-0.7%
Gross margin
76.3%
EPS (diluted)
−$0.30
+11.8% YoY · +74.1% QoQ

Source: XBRL data from the USANA HEALTH SCIENCES INC (USNA) Q4 2026 10-Q on SEC EDGAR. USD.

USANA HEALTH SCIENCES INC Q4 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $205.9M, down 3.6% YoY from $213.7M
  • Consolidated gross margin 76.3% vs 77.2% YoY, operating margin (0.7%) vs 0.6%
  • Best segment: Hiya revenue $31.5M, up 2.3%; worst: Rise revenue $3.6M, down 44.8%
  • Cash $178.9M vs $158.4M, operating cash flow $45.0M, financing outflows $17.8M
  • Headwinds: active Customers down 8.2%, challenging customer acquisition, Hiya digital marketing pressure in early 2026

Risk Factors

  • No explicit 10-Q risk-factor changes disclosed, limiting assessment of newly added risks
  • Hiya impairment risk: lower-than-expected performance and forecast changes triggered a $29,137 goodwill charge
  • Credit covenant risk: amended minimum EBITDA threshold reduced to $70,000 when revolving exposure stays below $50,000
  • Near-term operating risk: Hiya and Rise generated operating losses of $6,336 and $2,055 in the third quarter
  • Foreign-exchange risk: 2026 net-investment hedge carried a $61,766 notional amount

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other USANA HEALTH SCIENCES INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.